CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
// Ji-Young Kim 1, 2, * , Hwa-Yong Lee 3, * , Kwan-Kyu Park 4 , Yang-Kyu Choi 2 , Jeong-Seok Nam 5 , In-Sun Hong 6, 7 1 Center of Animal Care and Use, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea 2 Department of Laboratory Animal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Korea 3 The Faculty of Liberal Arts, Jungwon University, Chungbuk, Republic of Korea 4 Department of Pathology, College of Medicine, Catholic University of Daegu, Daegu, South Korea 5 School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea 6 Laboratory of Stem Cell Research, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, South Korea 7 Department of Molecular Medicine, School of Medicine, Gachon University, Incheon, Republic of Korea * These authors have contributed equally to this work Correspondence to: Jeong-Seok Nam, e-mail: namjs0206@gmail.com In-Sun Hong, e-mail: hongstem@gachon.ac.kr Keywords: CWP232228, cancer stem cells, Wnt/β-catenin signaling, CD133, ALDH Received: September 11, 2015 Accepted: January 16, 2016 Published: March 07, 2016 ABSTRACT Liver cancer stem cells (CSCs) are resistant to conventional chemotherapy and radiation, which may destroy tumor masses, but not all liver CSCs contribute to tumor initiation, metastasis, and relapse. In the present study, we showed that liver CSCs with elevated Wnt/β-catenin signaling possess much greater self-renewal and clonogenic potential. We further documented that the increased clonogenic potential of liver CSCs is highly associated with changes in Wnt/β-catenin signaling and that Wnt/β-catenin signaling activity is positively correlated with CD133 expression and aldehyde dehydrogenase (ALDH) enzymatic activity. Notably, the small molecule inhibitor CWP232228, which antagonizes the binding of β-catenin to TCF in the nucleus, inhibits Wnt/β-catenin signaling and depletes CD133 + /ALDH + liver CSCs, thus ultimately diminishing the self-renewal capacity of CSCs and decreasing tumorigenicity in vitro and in vivo . Taken together, our findings suggest that CWP232228 acts as a candidate therapeutic agent for liver cancer by preferentially targeting liver CSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of Hepatic Stem Cell Marker EpCAM by Wnt–β-Catenin Signaling in Hepatocellular Carcinoma
Yamashita, T., Budhu, A., Forgues, M., & Wang, X. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0908 · Cited by 446 · cited 2×
“Recent evidence has revealed the regulatory role of Wnt/β‐catenin signaling in maintaining liver CSCs [18, 30].”
BackgroundLachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., Villanueva, A., Minguez, B., Newell, P., Tsai, H.-W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2322 · Cited by 306
Shan, J., Shen, J., Liu, L., Xia, F., Xu, C., Duan, G., Xu, Y., Ma, Q., Yang, Z., Zhang, Q., et al. (2012) · Hepatology · doi:10.1002/hep.25745 · Cited by 296 · cited 4×
“Furthermore, recent studies have shown that the stem cell markers Oct4 [33], Sox2 [34], Nanog [35], and Klf4 [36] play important roles in regulating the self‐renewal of liver CSCs.”
BackgroundInfluential
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“CWP232228 is such an inhibitor, which was reported to induce apoptosis and cell cycle arrest in HCT116 cells,(380) also to show effects on liver and breast CSCs.(381,382) LF3, a 4-thioureido-benzenesulfonamide derivative, reduced tumor growth and induced differentiation in a CRC xenograft murine model.”
BackgroundWnt–β-catenin signalling in liver development, health and disease
Perugorria, M. J., Olaizola, P., Labiano, I., Esparza-Baquer, A., Marzioni, M., Marin, J. J. G., Bujanda, L., & Banales, J. M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0075-9 · Cited by 605
Katoh, M. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4129 · Cited by 465
Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer
Cheng, X., Xu, X., Chen, D., Zhao, F., & Wang, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.082 · Cited by 417
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies
Liu, Y.-C., Yeh, C.-T., & Lin, K.-H. (2020) · Cells · doi:10.3390/cells9061331 · Cited by 253
Hua, F., Shang, S., Yang, Y.-W., Zhang, H.-Z., Xu, T.-L., Yu, J.-J., Zhou, D.-D., Cui, B., Li, K., Lv, X.-X., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.10.031 · Cited by 171
Gajos-Michniewicz, A., & Czyz, M. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.050 · Cited by 89
Koelman, E. M. R., Yeste-Vázquez, A., & Grossmann, T. N. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116920 · Cited by 63
Selective Wnt/β-catenin Small-molecule Inhibitor CWP232228 Impairs Tumor Growth of Colon Cancer
KIM, J. Y., PARK, G., KRISHNAN, M., HA, E., & CHUN, K.-S. (2019) · Anticancer Research · doi:10.21873/anticanres.13514 · Cited by 18
Self-citationDai, Y., Guo, X., & Yang, C. (2020) · Oncology Letters · doi:10.3892/ol.2020.11678 · Cited by 8
Metadata
- Authors
- Kim, J.-Y., Lee, H.-Y., Park, K.-K., Choi, Y.-K., Nam, J.-S., & Hong, I.-S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-07
- Volume
- 7
- Issue
- 15
- Pages
- 20395-20409
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2294465717
- Cited by
- 74
- References
- 3
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.